Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 53,245 shares at $48.70 ($2.5M) on 2023-02-21, disclosed to the SEC on 2023-02-22.
Open-market sale of $2.5M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.54 | 22,895 | $1.1M | 42.8% |
| 2 | $46.54 | 22,895 | $1.1M | 42.8% |
| 3 | $47.35 | 2,200 | $104K | 4.2% |
| 4 | $48.70 | 2,502 | $122K | 4.9% |
| 5 | $48.70 | 2,502 | $122K | 4.9% |
| 6 | $49.60 | 251 |
| $12K |
| 0.5% |
| Total | $46.79 avg | 53,245 | $2.5M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |